For instance, for B cell lymphoma, the TLR1/2 agonist (Pam3CSK4) was applied with the conventional chemotherapeutic agent Ara-C, resulting in a synergistic anticancer effect through the up-regulation of immunomodulatory molecules [23]. Here, TLR1 is linked to B-cell non-Hodgkin lymphoma.